Sanofi (SNY) and Disc Medicine (IRON) saw reviews for their type 1 diabetes and rare blood disorder drugs postponed after U.S. Food and Drug Administration reviewers flagged safety and efficacy concerns, Reuters reported Thursday, citing internal documents.

The moves follow findings that included one patient death linked to Sanofi's Tzield and questions over the abuse potential for Disc Medicine's therapy, the report said.

The drugs are part of the Trump administration's fast-track National Priority Voucher Program, designed to cut review times to one or two months for medicines deemed critical to public health or national security, it said.

Reviews on two other drugs in the program, Boehringer Ingelheim's lung cancer therapy and Eli Lilly's (LLY) weight-loss pill, have also been delayed, with decisions now expected in mid-February and on April 10, respectively, Reuters said, citing the documents.

Disc Medicine, Sanofi, Boehringer Ingelheim and Eli Lilly did not immediately respond to MT Newswires' request for comment.

(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)